A PHASE-I/II TRIAL OF ZIDOVUDINE, INTERFERON-ALPHA, AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN THE TREATMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION

被引：61

作者：

DAVEY, RT ^{[1
]}

DAVEY, VJ ^{[1
]}

METCALF, JA ^{[1
]}

ZURLO, JJ ^{[1
]}

KOVACS, JA ^{[1
]}

FALLOON, J ^{[1
]}

POLIS, MA ^{[1
]}

ZUNICH, KM ^{[1
]}

MASUR, H ^{[1
]}

LANE, HC ^{[1
]}

机构：

[1] NIH, DEPT CRIT CARE MED, BETHESDA, MD 20892 USA

来源：

JOURNAL OF INFECTIOUS DISEASES | 1991年 / 164卷 / 01期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1093/infdis/164.1.43

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Twenty-four patients infected with human immunodeficiency virus type 1 (HIV-1) who had CD4+ counts of 0.2-0.5 x 10(9) cells/l received granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with zidovudine plus escalating doses of daily subcutaneous interferon-alpha. Mean neutropenia-inducing doses of interferon-alpha were 9.4 x 10(6) and 10.6 x 10(6) IU/day for groups receiving 100 or 200 mg zidovudine every 4 h, respectively. Mean GM-CSF doses used to reverse neutropenia were 0.64 and 0.63-mu-g/kg/day for these two groups, respectively, although the mean minimum effective GM-CSF dose for both was only 0.30-mu-g/kg/day. Serum p24 antigen declined > 70% in all 5 antigenemic patients. Toxicities included a dose-dependent increase in lymphokine-like side effects (100%), anorexia and weight loss (42%), fatigue (42%), and anemia (50%). While toxicities of the combination can be significant, low-dose GM-CSF readily ameliorated neutropenia associated with zidovudine and interferon-alpha therapy without adversely affecting the antiviral properties of the combination.

引用

页码：43 / 52

页数：10

共 39 条

[1] EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON CHEMOTHERAPY-INDUCED MYELOSUPPRESSION [J].